Medicus Pharma Ltd. · NASDAQ:MDCX

Medicus Pharma — Q3 2026 Earnings Presentation

30 slides from Medicus Pharma's earnings presentation, Nov 9, 2026

  1. Slide 1: Corporate Presentation Q3 2026

    Corporate Presentation Q3 2026 (NASDAQ: MDCX) NASDAQ: MDCX

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement Certain information in this presentation constitutes "forward-looking statements" or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements

  3. Slide 3: About Medicus Pharma

    About Medicus Pharma A precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and poten tially disruptive therapeutic assets designed to transform the standard of care. De-risking and Partnering Business Strategy Our strategy is to advance s

  4. Slide 4: Portfolio Companies

    Portfolio Companies A clinical-stage oncology company building a portfolio of differentiated, high- potential oncology programs. Our foundational asset is CD228V ADC, an investigational antibody drug conjugate molecule utilizing Pfizer established vedotin linker payload platform, directed against me

  5. Slide 5: Introducing a Potential First-in-Class CD228-Targeted ADC

    Introducing a Potential First-in-Class CD228-Targeted ADC Investigational molecule utilizing established vedotin linker-payload platform, directed against a cell-surface protein expressed across multiple solid tumor types, such as melanoma collectively representing potentially a multi-billion dollar

  6. Slide 6: ADCs Are Reshaping Oncology

    ADCs Are Reshaping Oncology Recent ADC successes Enhertu Trodelvy >$60B Projected global ADC market HER2-directed Breast, gastric & lung cancers TROP2-directed Breast & bladder cancers ADCs are one of the most valuable and fastest-growing modalities in oncology Padcev Adcetris Nectin-4 / MMAE CD30 /

  7. Slide 7: The ADC Landscape Is Layered by Target Maturity

    The ADC Landscape Is Layered by Target Maturity Most competition concentrates on validated targets — CD228 sits in open, emerging white space LAYER A HER2 · Enhertu TROP2 · Trodelvy Nectin-4 · Padcev Validated & Crowded Proven targets with approved ADCs and intense competition High competition Targe

  8. Slide 8: Competitive Landscape

    Competitive Landscape Where CD228V is differentiated BA1302 Shandong Boan Biotech Clinical lineage Vedotin platform Anti-CD228 ADC CD228V is built on the Seagen/Pfizer Established vedotin/MMAE membrane-CD228 specific clinical lineage with prior human linker-payload technology with shared profile exp

  9. Slide 9: Seamless Phase 1/2 clinical development program

    Seamless Phase 1/2 clinical development program First-in-human dose escalation study* initiated with seven melanoma patients (2L+ post-I/O) enrolled across two dose levels PART A PART B PART C Dose Escalation Dose Optimization Expansion Cohorts Part A · safety + dose Part B · RP2D selection Part C ·

  10. Slide 10: CD228V Mechanism of Action

    CD228V Mechanism of Action A targeted vedotin (MMAE) payload delivered to CD228-expressing tumor cells • CD228 is a membrane-bound glycoprotein with a possible role in tumor-cell migration and proliferation. It is highly expressed in melanoma and other solid tumors with limited expression in normal

  11. Slide 11: CD228 ADC | IP Portfolio

    CD228 ADC | IP Portfolio Issued U.S. Patents U.S. Patent 11,617,798 Patent composition Anti-CD228 antibodies, antibody-drug conjugate comprising an anti-CD228 Exclusive worldwide rights to antibody and a cytotoxic or cytostatic drug (e.g. MMAE), methods of treating cancer with antibody-drug conjugat

  12. Slide 12: Introducing SkinJect

    Introducing SkinJect® A novel, localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients. Gorlin Syndrome (Nevoid BCC) Reducing lifelong surgical burden in a rare autosomal dominant, multi-lesion genetic disease ~150 patients treated across

  13. Slide 13: Gorlin Syndrome (Nevoid Basal Cell Carcinoma) Market Opportunity

    Gorlin Syndrome (Nevoid Basal Cell Carcinoma) Market Opportunity An autosomal-dominant rare disease with an FDA-authorized registrational path affecting approximately 1 in 31,000 people worldwide and ~11,000 patients in United States with active BCC Market Outlook An independent commercial assessmen

  14. Slide 14: BCC | Treatment outcomes

    BCC | Treatment outcomes SkinJect® provides complete skin clearance – Mohs surgery may result in lumpy scarring Untreated Basal Cell Carcinoma (BCC) BCC treated with SkinJect® Patch* BCC treated with Mohs Surgery Basal Cell Carcinoma (BCC) Basal Cell Carcinoma BCC treated withCarcinoma Basal Cell Mo

  15. Slide 15: SkinJect Phase 2 Results

    SkinJect® Phase 2 Results1 The 200-µg D-MNA cohort demonstrated the strongest therapeutic response on Day 57: Dose # of patients(n) Day 29 post-treatment # of patients(n) Day 57 post-treatment Clinical Histological Clinical Histological 37 34 Clearance Clearance (CR) Clearance Clearance (CR) Device

  16. Slide 16: SkinJect Clinical Development Outlook

    SkinJect® Clinical Development Outlook Nevoid BCC (Gorlin H2 2028 Syndrome) H1 2027 File NDA with FDA • Ph2 trial initiation H2 2026 • Pivotal Study Approved (~40 patients) H1 2026 • File Orphan Drug Designation • File IND • File Rare Disease Voucher H1 2026 • +Ve Top Line Phase 2 Data (64% CC; 55%

  17. Slide 17: SkinJect | IP Portfolio

    SkinJect® | IP Portfolio Issued U.S. Patents U.S. Patent 9,944,019 B2 Tip-Loaded Microneedle Arrays for Transdermal Insertion. (Natural Expiration: Patent composition 2033) Worldwide right and exclusive U.S. Patents 11,744,927 & 8,834,423 license to make, use, or sell licensed technology and practic

  18. Slide 18: Introducing Teverelix

    Introducing Teverelix® Clinical-stage, next-generation injectable long-acting GnRH antagonist FIRST-IN-CLASS BEST-IN-CLASS PRECISION-LED Acute Urinary Retention Advanced Prostate Cancer Severe-to-Moderate (AUR) (APC) Endometriosis Preventing recurrence after a first Patients with increased First pro

  19. Slide 19: Teverelix Clinical Development Outlook

    Teverelix® Clinical Development Outlook H1 2030 Ph2 trial readout H2 2028 Interim analysis Read out H1 2027 Ph 2 trial initiation Secure IND AUR $2b Opportunity AUR: acute urinary retention, APC: advanced prostate cancer, IND: Investigational New Drug, CMC: Chemistry, Manufacturing, and Controls NAS

  20. Slide 20: First-in-Class Teverelix Opportunity in Acute Urinary Retention

    First-in-Class Teverelix® Opportunity in Acute Urinary Retention 85% of nearly 1m annual AUR episodes in USA occur in men aged 60+ Urine in bladder who suffer from enlarged prostate that manifests with age and frequently is followed by a recurrent episode within 6 months for over 30% of men Normal G

  21. Slide 21: Treatment Pathway Landscape in AUR

    Treatment Pathway Landscape in AUR Teverelix® may prevent recurrence of AUR by reducing prostate size significantly >90% pts <4 weeks vs >6 months by 5-ARIs Add 5-alpha reductase inhibitors (5-ARIs) Bladder Treatment Recurrent First AUR decompression with α1- TWOC AUR episode by catheterization bloc

  22. Slide 22: Teverelix: Rapid Reduction in Prostate Size May Prevent Recurrence of AUR

    Teverelix®: Rapid Reduction in Prostate Size May Prevent Recurrence of AUR Prostate size reduction Prostate volume strongly correlates with Change in mean prostate size decreased by 11% efficacy in surgery as well BL Time (weeks) BPH medications 0.0% 0 4 8 12 16 Phase 2 Prostate volume (cm3) -3.0% N

  23. Slide 23: Phase 2b design for AUR

    Phase 2b design for AUR FDA GUIDANCE RECEIVED PATIENT RECRUITMENT 28 weeks STUDY SoC2 + Single PRIMARY AUR Teverelix® is aiming Teverelix® IM injection TVX ENDPOINT to be the First-in- – 90mg IM 90 Total prostate volume Indication product (TPV) reduction for “preventing 126 patients - recurrence of

  24. Slide 24: Advanced Prostate Cancer Patients with High Cardiovascular Risk

    Advanced Prostate Cancer (APC) Patients with High Cardiovascular (CV) Risk Teverelix® is the first GnRH antagonist designed and trialled specifically for patients with cardiovascular vulnerability with the aim of generating evidence capable of supporting cardiovascular differentiation in the label G

  25. Slide 25: Teverelix Ph3 Registration Study

    Teverelix® Ph3 Registration Study Unlike GnRH agonists, GnRH antagonists suppress testosterone directly without the initial testosterone surge and have generated evidence suggesting a potentially more favorable cardiovascular profile; particularly relevant in men with pre-existing cardiovascular dis

  26. Slide 26: PRECISION-E2: Genomic-Guided Precision Medicine Study in Endometriosis

    PRECISION-E2: First Prospective Genomic-Guided Precision Medicine Study in Endometriosis Potential first genomic-guided GnRH antagonist development program in endometriosis leveraging UAE national genomic infrastructure. Patient Flow Prospective enrollment from genomically characterized population •

  27. Slide 27: Teverelix | IP Portfolio

    Teverelix® | IP Portfolio New composition of matter IP in USA, EU and Japan until 2039 and Orange Book IP until 2044/45 IP and Orange Book IP 067728 – EU, USA, CHN - 2039 Teverelix TFA molar ratio composition 067718 – EU, USA, J - 2039 Patent composition A reconstitutable teverelix TFA composition M

  28. Slide 28: Financial Summary

    Financial Summary Balance Sheet as of June 30th ,2026(in USD millions) Cap Table as of June 30th 2026 Cash and Cash Equivalent Incl. restricted cash $25.2 Common Shares Outstanding 60,168,044 (Adjusted) Stock Options Outstanding2 5,510,000 Total Assets $27 Pref. Equity 0 Debt1 $21.5 Warrants3 7,281,

  29. Slide 29: Leadership

    Leadership Raza Bokhari, MD Management Exec. Chairman & CEO Carolyn Bonner Andrew Smith Maryann Adesso Faisal Mehmud, MD Viktoriia Slepeniuk Anna Baran-Djokovic President & CFO Chief Operating Officer Chief of Staff Chief Medical Officer SVP, Public Relations SVP, Investor Relations Directors Board

  30. Slide 30: Thank you!

    ty M EL ICU S Thank you! NASDAQ: MDCX

Medicus Pharma — Q3 2026 Earnings Presentation on 6ix